In most cases (85 percent), the stroke is caused by the occlusion of a blood vessel in the brain. This results in the affected area of the brain becoming undersupplied with blood and oxygen, causing nerve tissue to die off beyond retrieval. Despite intensive research activities, only inadequate treatment options are currently available. The medical engineering company MD-5 GmbH, founded with the support of Fraunhofer IZI, has set itself the goal of improving this situation using an innovative treatment method.
The therapy concept developed by MD-5 GmbH is based on a procedure which can specifically influence the blood flow in the brain using magnetic fields. So-called intelligent transcranial magnetic stimulation (iTMS) allows blood flow to be increased in defined regions of the brain, thus limiting damage caused by a stroke. “Several investigations and optimizations are still required before the technology can be introduced into clinical routine as a medical device. Together with the Fraunhofer IZI and Leipzig University Hospital, we look forward to continuing with the development of a prototype which is suitable for practice and preparing its market launch,” commented Dr. Mark K. Borsody, Founder and Chief Medical Officer, describing the cooperation work of the joint project.
“The Fraunhofer IZI is contributing its comprehensive expertise in the areas of stroke research and preclinical development. Expressive model systems are to verify both the safety and efficacy of the procedure. The procedure can then be optimized accordingly by our colleagues at MD-5, based on these investigations,” commented Dr. Antje Dreyer, Head of the Clinic-oriented Therapy Assessment Unit at Fraunhofer IZI, describing the Fraunhofer Institute's role in the project.
With the addition of MD-5 GmbH, founded in Leipzig in October 2012 as a subsidiary of the US company Lake Bioscience LLC, Fraunhofer IZI has managed to bring on board another international partner and increase investment in the biotechnology location of Saxony.
“We are very glad that we succeded in convincing our colleagues from Lake Biosciences to establish their european subsidiary in Leipzig / Saxony” adds Dr. Thomas Tradler, Head of Business Development at the Fraunhofer IZI.
The project, valued at a total of 1.4 million euros, is being funded through the Sächsische Aufbaubank (Saxon Development Bank) with a total of 1.1 million euros coming from the European Regional Development Fund (ERDF) and also from the Free State of Saxony.
The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops specific problem solutions at the interfaces of medicine, life sciences and engineering. The Institute practices contract research for biotechnological, pharmaceutical and medical-technological companies, hospitals, diagnostic laboratories and research facilities. Within the Business Units of Agents, Cell Therapy, Diagnostic and Biobanking, the Institute develops, optimizes and validates methods, materials and products. The Institute's core competencies are located in the field of Regenerative Medicine, in particular in the indication areas of oncology, ischemia and autoimmune, inflammatory and infectious diseases. The Institute is clinically oriented and conducts quality checks and the GMP-compliant manufacture of investigational medicinal products. Moreover, the Institute provides support in obtaining manufacturing authorizations and approvals.
Novel breast tomosynthesis technique reduces screening recall rate
21.02.2017 | Radiological Society of North America
Biocompatible 3-D tracking system has potential to improve robot-assisted surgery
17.02.2017 | Children's National Health System
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
22.02.2017 | Power and Electrical Engineering
22.02.2017 | Life Sciences
22.02.2017 | Physics and Astronomy